# Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

> **NCT06603987** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Stella Pharma Corporation** · enrollment: 30 (estimated)

## Conditions studied

- Thoracic Solid Malignant Tumor

## Interventions

- **RADIATION:** BNCT
- **DIAGNOSTIC_TEST:** ［18F］FBPA

## Key facts

- **NCT ID:** NCT06603987
- **Lead sponsor:** Stella Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-10
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603987, "Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06603987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*